Latest & greatest articles for multiple sclerosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on multiple sclerosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on multiple sclerosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for multiple sclerosis

41. Multiple sclerosis: wasted opportunities

Multiple sclerosis: wasted opportunities Prescrire IN ENGLISH - Spotlight ''Multiple sclerosis: wasted opportunities'', 1 April 2019 {1} {1} {1} | | > > > Multiple sclerosis: wasted opportunities Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Multiple sclerosis: wasted opportunities The drugs on the market have been so poorly evaluated (...) that healthcare professionals are not able to make the best use of the available treatments, to the detriment of patients. Numerous drugs have been authorised over the past 15 years for treatment of multiple sclerosis. Eight drugs have been authorised in Europe since the market introduction of interferon beta (Avonex°, Betaferon° or other brands) and glatiramer (Copaxone° or other brands). These eight drugs were granted marketing authorisation on the basis of 16 clinical trials, 11 of which compared the new

2019 Prescrire

42. Multiple sclerosis

Multiple sclerosis Multiple sclerosis - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Multiple sclerosis Last reviewed: February 2019 Last updated: February 2019 Summary Demyelinating central nervous system condition clinically defined by two episodes of neurological dysfunction (brain, spinal cord, or optic nerves) that are separated in space and time. Classically presents in white women, aged between 20 to 40 years (...) , but lends greater specificity when present with brain lesions. Treatment of the condition can be divided into three parts: treatment of the acute attack; prevention of future attacks by reducing triggers and use of disease-modifying therapies; and symptomatic treatments of neurological difficulties such as spasticity, pain, fatigue, and bladder dysfunction. Definition Multiple sclerosis (MS) is defined as an inflammatory demyelinating disease characterised by the presence of episodic neurological

2019 BMJ Best Practice

43. Web-based physiotherapy for people affected by multiple sclerosis: a single blind, randomized controlled feasibility study Full Text available with Trip Pro

Web-based physiotherapy for people affected by multiple sclerosis: a single blind, randomized controlled feasibility study To examine the feasibility of a trial to evaluate web-based physiotherapy compared to a standard home exercise programme in people with multiple sclerosis.Multi-centre, randomized controlled, feasibility study.Three multiple sclerosis out-patient centres.A total of 90 people with multiple sclerosis (Expanded Disability Status Scale 4-6.5).Participants were randomized

2019 EvidenceUpdates

44. Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosis Full Text available with Trip Pro

Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosis To examine whether rituximab induction followed by glatiramer acetate (GA) monotherapy is more effective than GA alone for the treatment of relapsing multiple sclerosis with active disease.This was a single-center, double-blind, placebo-controlled study. Fifty-five participants were randomly assigned (1:1 ratio) to either rituximab (R-GA) or placebo (P-GA) induction, followed by GA therapy initiated (...) the study period. There were no differences in adverse events.Induction therapy with rituximab followed by GA may provide superior efficacy in the short term than GA alone in relapsing multiple sclerosis, but this benefit appears to wane within the study period. Larger studies are needed to assess sustainability of results.NCT01569451.© 2019 American Academy of Neurology.

2019 EvidenceUpdates

45. Percutaneous venoplasty for chronic cerebrospinal venous insufficiency in multiple sclerosis

Percutaneous venoplasty for chronic cerebrospinal venous insufficiency in multiple sclerosis P Percutaneous v ercutaneous venoplasty for chronic enoplasty for chronic cerebrospinal v cerebrospinal venous insufficiency in multiple enous insufficiency in multiple sclerosis sclerosis Interventional procedures guidance Published: 30 January 2019 nice.org.uk/guidance/ipg640 Y Y our responsibility our responsibility This guidance represents the view of NICE, arrived at after careful consideration (...) 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 1 of 41 1 Recommendations Recommendations 1.1 Current evidence on percutaneous venoplasty for chronic cerebrospinal venous insufficiency in multiple sclerosis shows that there are serious complications and that it provides no benefit. Therefore, this procedure should not be used in the management of multiple sclerosis. 2 2 The condition, current treatments and procedure

2019 National Institute for Health and Clinical Excellence - Interventional Procedures

46. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. Full Text available with Trip Pro

Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. Within 2 decades of onset, 80% of untreated patients with relapsing-remitting multiple sclerosis (MS) convert to a phase of irreversible disability accrual termed secondary progressive MS. The association between disease-modifying treatments (DMTs), and this conversion has rarely been studied and never using a validated definition.To determine the association between the use

2019 JAMA

47. Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial. Full Text available with Trip Pro

Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial. Hematopoietic stem cell transplantation (HSCT) represents a potentially useful approach to slow or prevent progressive disability in relapsing-remitting multiple sclerosis (MS).To compare the effect of nonmyeloablative HSCT vs disease-modifying therapy (DMT) on disease

2019 JAMA Controlled trial quality: predicted high

48. Rehabilitation for people with multiple sclerosis: an overview of Cochrane Reviews. Full Text available with Trip Pro

Rehabilitation for people with multiple sclerosis: an overview of Cochrane Reviews. Multiple sclerosis (MS) is a major cause of chronic, neurological disability, with a significant long-term disability burden, often requiring comprehensive rehabilitation.To systematically evaluate evidence from published Cochrane Reviews of clinical trials to summarise the evidence regarding the effectiveness and safety of rehabilitation interventions for people with MS (pwMS), to improve patient outcomes (...) , and to highlight current gaps in knowledge.We searched the Cochrane Database of Systematic Reviews up to December 2017, to identify Cochrane Reviews that assessed the effectiveness of organised rehabilitation interventions for pwMS. Two reviewers independently assessed the quality of included reviews, using the Revised Assessment of Multiple Systematic Reviews (R-AMSTAR) tool, and the quality of the evidence for reported outcomes, using the GRADE framework.Overall, we included 15 reviews published

2019 Cochrane

49. A Controlled Clinical Trial on the Effects of Exercise on Cognition and Mobility in Adults With Multiple Sclerosis. Full Text available with Trip Pro

A Controlled Clinical Trial on the Effects of Exercise on Cognition and Mobility in Adults With Multiple Sclerosis. The aim of the study was to investigate the effects of a 6-mo exercise program on cognition and mobility in participants with multiple sclerosis.This is a prospective, single-blind, controlled clinical trial.A community rehabilitation program within a large metropolitan health service.Twenty-eight patients with multiple sclerosis were referred for outpatient (...) did not have significant changes in cognition scores after 6 mos of follow-up and had a worse performance in mobility tests.Six months of exercise provided benefits to cognition and mobility in adults with multiple sclerosis. This trial was registered prospectively with the Brazilian Clinical Trials Register, ID: RBR-9gh4km (http://www.ensaiosclinicos.gov.br/rg/?q=RBR-9gh4km).Complete the self-assessment activity and evaluation online at http://www.physiatry.org/JournalCME CME OBJECTIVES: Upon

2019 American journal of physical medicine & rehabilitation Controlled trial quality: uncertain

50. Multiple sclerosis

Multiple sclerosis Multiple sclerosis | Topics A to Z | CKS | NICE Search CKS… Menu Multiple sclerosis Multiple sclerosis Last revised in October 2019 Multiple sclerosis (MS) is a presumed autoimmune inflammatory condition of the central nervous system (CNS) resulting in areas of demyelination Diagnosis Management Prescribing information Background information Multiple sclerosis: Summary Multiple sclerosis (MS) is a presumed autoimmune inflammatory condition of the central nervous system (CNS

2019 NICE Clinical Knowledge Summaries

51. Natalizumab for the Treatment of Relapsing-Remitting Multiple Sclerosis. HTA-Projektbericht 112.

Natalizumab for the Treatment of Relapsing-Remitting Multiple Sclerosis. HTA-Projektbericht 112. Natalizumab for the Treatment of Relapsing-Remitting Multiple Sclerosis - Repository of AIHTA GmbH English | Browse - - - Natalizumab for the Treatment of Relapsing-Remitting Multiple Sclerosis Fuchs, E. (2019): Natalizumab for the Treatment of Relapsing-Remitting Multiple Sclerosis. HTA-Projektbericht 112. Preview - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. , oder 659kB (...) Abstract Introduction: Worldwide, more than 2.5 million people suffer from Multiple Sclerosis (MS), which is a progressive degenerating disease of the central nervous system (CNS). At present, there is no definitive cure. Thus, available pharmacological therapies aim to reduce the disease activity by either suppressing or modulating the immune system. The humanised monoclonal antibody natalizumab (Tysabri™) was approved for the treatment of relapsing-remitting MS by the FDA and the EMA in 2006

2019 Austrian Institute of Health Technology Assessment

52. Siponimod for the Treatment of Secondary Progressive Multiple Sclerosis: Effectiveness and Value

Siponimod for the Treatment of Secondary Progressive Multiple Sclerosis: Effectiveness and Value ©Institute for Clinical and Economic Review, 2019 Siponimod for the Treatment of Secondary Progressive Multiple Sclerosis: Effectiveness and Value Final Evidence Report June 20, 2019 Prepared for ©Institute for Clinical and Economic Review, 2019 Page i Final Evidence Report – Siponimod for Secondary Progressive MS ICER Staff and Consultants University of Washington School of Pharmacy Modeling Group (...) of the authors above disclosed any conflicts of interest. We would also like to thank Jeffrey A. Tice, MD, of the University of California, San Francisco, whose work on ICER’s 2017 review of Disease-Modifying Therapies for Relapsing-Remitting and Primary-Progressive Multiple Sclerosis helped to inform the background and definitions section of the current report. ©Institute for Clinical and Economic Review, 2019 Page ii Final Evidence Report – Siponimod for Secondary Progressive MS About ICER The Institute

2019 California Technology Assessment Forum

53. Ocrelizumab (Ocrevus) - relapsing forms of multiple sclerosis

Ocrelizumab (Ocrevus) - relapsing forms of multiple sclerosis 1 Published 10 December 2018 1 SMC2121 ocrelizumab 300mg concentrate for solution for infusion (Ocrevus®) Roche Products Ltd Resubmission 9 November 2018 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a resubmission ocrelizumab (Ocrevus® (...) ) is accepted for restricted use within NHSScotland. Indication under review: The treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features. SMC restriction: Treatment of relapsing remitting multiple sclerosis (RRMS) in adults with active disease defined by clinical or imaging features who are contra-indicated or otherwise unsuitable for alemtuzumab. Two phase III studies identified superiority of ocrelizumab when compared

2018 Scottish Medicines Consortium

54. Multiple Sclerosis-Associated Changes in the Composition and Immune Functions of Spore-Forming Bacteria Full Text available with Trip Pro

Multiple Sclerosis-Associated Changes in the Composition and Immune Functions of Spore-Forming Bacteria Multiple sclerosis (MS) is an autoimmune disease of the central nervous system characterized by adaptive and innate immune system dysregulation. Recent work has revealed moderate alteration of gut microbial communities in subjects with MS and in experimental, induced models. However, a mechanistic understanding linking the observed changes in the microbiota and the presence of the disease

2018 mSystems

55. ADSTEP: Preliminary Investigation of a Multicomponent Walking Aid Program in People With Multiple Sclerosis Full Text available with Trip Pro

ADSTEP: Preliminary Investigation of a Multicomponent Walking Aid Program in People With Multiple Sclerosis To evaluate the effect of the Assistive Device Selection, Training and Education Program (ADSTEP) on falls and walking and sitting activity in people with multiple sclerosis (PwMS).Randomized controlled trial.Veterans affairs medical center.PwMS (N=40) using a walking aid at baseline who had fallen in the previous year.Participants were randomly assigned to ADSTEP or control. ADSTEP had 6 (...) Technologies, Multiple Sclerosis Walking Scale-12, Activities-Specific Balance Confidence Scale, and Multiple Sclerosis Impact Scale-29. Effect on these outcomes was estimated by a 2-by-2 repeated measures general linear model.Fewer ADSTEP than control participants fell (χ2=3.96, P<.05. number needed to treat =3.3). Time spent sitting changed significantly differently with ADSTEP than with control from baseline to intervention completion (F=11.16, P=.002. ADSTEP: reduced 87.00±194.89min/d; control

2018 EvidenceUpdates

56. Fampridine (Fampyra) - multiple sclerosis

Fampridine (Fampyra) - multiple sclerosis 1 Published 12 November 2018 1 SMC2107 fampridine 10mg prolonged-release tablet (Fampyra®) Biogen Idec Ltd Resubmission 05 October 2018 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a resubmission fampridine (Fampyra ® ) is not recommended for use within (...) NHSScotland. Indication under review: For the improvement of walking in adult patients with multiple sclerosis with walking disability (EDSS [expanded disability status scale] 4-7). In double-blind phase III studies fampridine, compared with placebo, improved walking ability in adults with multiple sclerosis and walking impairment. The submitting company did not present a sufficiently robust economic analysis to gain acceptance by SMC. Chairman Scottish Medicines Consortium www.scottishmedicines.org.uk 2

2018 Scottish Medicines Consortium

57. Information provision for people with multiple sclerosis. Full Text available with Trip Pro

Information provision for people with multiple sclerosis. People with multiple sclerosis (MS) are confronted with a number of important uncertainties concerning many aspects of the disease. These include diagnosis, prognosis, disease course, disease-modifying therapies, symptomatic therapies, and non-pharmacological interventions, among others. While people with MS demand adequate information to be able to actively participate in medical decision making and to self manage their disease, it has (...) to promote informed choice and improve patient-relevant outcomes, Further objectives were to evaluate the components and the developmental processes of the complex interventions used, to highlight the quantity and the certainty of the research evidence available, and to set an agenda for future research.For this update, we searched the Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group Specialised Register, which contains trials from CENTRAL (the Cochrane Library 2017

2018 Cochrane

58. Relationship Between Physiological and Perceived Fall Risk in People With Multiple Sclerosis: Implications for Assessment and Management Full Text available with Trip Pro

Relationship Between Physiological and Perceived Fall Risk in People With Multiple Sclerosis: Implications for Assessment and Management This study evaluated the relationship between physiological and perceived fall risk in people with multiple sclerosis (MS).Secondary analysis of data from prospective cohort studies undertaken in Australia, the United Kingdom, and the United States.Community.Ambulatory people with MS (N=416) (age 51.5±12.0 years; 73% female; 62% relapsing-remitting MS; 13.7

2018 EvidenceUpdates

59. Diagnostic and Clinical Utility of the GAD-2 for Screening Anxiety Symptoms in Individuals With Multiple Sclerosis Full Text available with Trip Pro

Diagnostic and Clinical Utility of the GAD-2 for Screening Anxiety Symptoms in Individuals With Multiple Sclerosis To assess the diagnostic and clinical utility of the 2-item Generalized Anxiety Disorder Scale (GAD-2) for screening anxiety symptoms in individuals with multiple sclerosis (MS).Cross-sectional.University-affiliated MS neurology and rehabilitation center.The sample comprised adults (N=99) (ages 19-72; mean ± SD=46.2±13.0; 75% women) with a physician-confirmed MS diagnosis who were

2018 EvidenceUpdates

60. Discriminative ability and clinical utility of the Timed Up and Go (TUG) in identifying falls risk in people with multiple sclerosis: a prospective cohort study (Abstract)

Discriminative ability and clinical utility of the Timed Up and Go (TUG) in identifying falls risk in people with multiple sclerosis: a prospective cohort study To investigate discriminative ability and clinical utility of the Timed Up and Go under single- and dual-task conditions between fallers and non-fallers in multiple sclerosis (MS).Prospective cohort study.Neurology service in a tertiary hospital.Participants were 101 people with MS and Expanded Disability Status Scale score of 3-6.5 (...) -Cognitive in distinguishing fallers (person with ⩾1 fall) from non-fallers are 0.60 and 0.57, respectively, and in distinguishing multiple fallers (⩾2 falls) the values are 0.46 and 0.43. A Timed Up and Go score of ⩾9 seconds has a sensitivity of 0.82 and a specificity of 0.34 to identify fallers and a sensitivity of 0.79 and a specificity of 0.27 to identify multiple fallers. A Timed Up and Go-Cognitive score of ⩾11 seconds has a sensitivity of 0.77 and a specificity of 0.30 to identify fallers

2018 EvidenceUpdates